RecruitingPhase 1NCT07205289
Serum Collection Study for Assay Development
A Phase 1B Open-label Study to Collect Serum Following Vaccination With Killed Whole-cell Pneumococcal Vaccine (Gamma-PN) in Adults for Use in Assay Validation
Sponsor
GPN Vaccines
Enrollment
12 participants
Start Date
Oct 1, 2025
Study Type
INTERVENTIONAL
Conditions
Summary
The study will collect serum from 12 participants vaccinated with Gamma-PN to assist with assay development and validation
Eligibility
Min Age: 18 YearsMax Age: 69 Years
Inclusion Criteria1
- good general health
Exclusion Criteria1
- no previous pneumococcal vaccine
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALGamma-PN
Killed whole-cell pneumococcal vaccine
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07205289